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In this study, we investigated the kinetics of oxaliplatin-DNA adduct formation in white blood cells of cancer patients in relation to
efficacy as well as oxaliplatin-associated neurotoxicity. Thirty-seven patients with various solid tumours received 130mgm
 2
oxaliplatin as a 2-h infusion. Oxaliplatin-DNA adduct levels were measured in the first cycle using adsorptive stripping voltammetry.
Platinum concentrations were measured in ultrafiltrate and plasma using a validated flameless atomic absorption spectrometry
method. DNA adduct levels showed a characteristic time course, but were not correlated to platinum pharmacokinetics and varied
considerably among individuals. In patients showing tumour response, adduct levels after 24 and 48h were significantly higher than in
nonresponders. Oxaliplatin-induced neurotoxicity was more pronounced but was not significantly different in patients with high
adduct levels. The potential of oxaliplatin-DNA adduct measurements as pharmacodynamic end point should be further investigated
in future trials.
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Oxaliplatin is a third-generation diaminocyclohexane (DACH)-
platinum complex with lacking cross-resistance against cisplatin
and carboplatin. Oxaliplatin is part of the therapeutic standard
regimens for the treatment of metastatic colorectal cancer in
combination with fluorouracil/leucovorin (Giacchetti et al, 2000;
de Gramont et al, 2000). Oxaliplatin has also been used as a single
agent in this disease and other malignancies (Faivre et al, 1999;
Germann et al, 1999; Garufi et al, 2001). Besides treatment of
patients with metastatic disease, oxaliplatin is also approved for
adjuvant protocols (Andre ´ et al, 2004). However, neurotoxicity in
the form of transient neuropathy and a persistent cumulative
typical sensory polyneuropathy is common and dose-limiting,
whereas other types of toxicity associated with platinum complexes
are rare or of minor severity (Cassidy and Misset, 2002; Gamelin
et al, 2002; Grothey, 2003).
Similar to other platinum coordination complexes, the cytotoxic
activity is based upon the formation of mono- or bifunctional
adducts with DNA (Scheeff et al, 1999; Le ´vi et al, 2000). Among
other factors, the platinum-DNA adduct levels are influenced by
drug uptake, drug efflux and DNA repair (Fink et al, 1997;
Raymond et al, 2002; Faivre et al, 2003). As the degree of DNA
platination plays a central role in the mechanism of action of
platinum complexes, the determination of platinum-DNA adducts
formed in the tumour tissue might be of interest for individual
dose adaptation. However, the poor accessibility of tumour tissue
is a major obstacle for routine measurement. Therefore, white
blood cells (WBC) have been considered as surrogate cells (Reed
et al, 1988; Poirier et al, 1992; Nadin et al, 2006). Various clinical
studies with cisplatin have shown that tumour response is related
to platinum-DNA adduct levels in WBC (Reed et al, 1987; Parker
et al, 1991; Schellens et al, 1996).
The platinum-DNA adduct formation in WBC was found to be
highly predictive for tumour response after platinum-based
therapy and even more predictive than platinum pretreatment,
stage of disease, histological type and tumour grading (Reed et al,
1990). Recently, a significantly better disease-free survival was
reported for cisplatin-treated head and neck carcinoma patients
with higher adduct levels (Hoebers et al, 2006). The feasibility of
intraindividual dose escalation of cisplatin based on platinum-
DNA adduct levels has been shown in two clinical trials in patients
with head and neck cancer (Schellens et al, 2001) and non-small
cell lung cancer (Schellens et al, 2003). However, not all
investigators found a relationship between adduct levels and
tumour response. It has been speculated that the technique of the
adduct measurement, the tumour types investigated, and medica-
tion factors could have influenced the adduct levels and led to
conflicting results (Motzer et al, 1994; Bonetti et al, 1996).
For oxaliplatin, only two reports were published on adduct
levels, each in six patients (Allain et al, 1996; Liu et al, 2002).
Studies investigating a larger number of patients and a potential
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srelationship to tumour response and toxicity have not been
performed as yet. For the first time, we report here the platinum-
DNA adduct levels in WBC of patients receiving oxaliplatin in the
context of a clinical study.
Measurement of platinum-DNA adduct levels in WBC has been
successfully applied in cancer patients receiving cisplatin and
high-dose carboplatin using flameless atomic absorption spectro-
metry (Kloft et al, 1999b). Because of the generally lower extent of
platinum-DNA adduct formation after administration of oxaliplatin
(Raymond et al, 2002), we used the more sensitive adsorptive
stripping voltammetry to quantify DNA-bound platinum (Weber
et al, 2004).
This study was designed to assess both time-dependence and
interindividual variability of platinum-DNA adduct formation in
relation to pharmacokinetics in plasma and ultrafiltrate after
administration of oxaliplatin as well as to detect potential
relationships with efficacy and/or toxicity.
PATIENTS AND METHODS
Patients
Blood sampling was performed within a single-centre, open-label,
non-placebo-controlled, nonrandomised phase I study that was
conducted to investigate the safety, pharmacokinetics and efficacy
of sorafenib (BAY 43-9006), a multikinase inhibitor, in combina-
tion with oxaliplatin (Kupsch et al, 2005). The study protocol was
approved by the local ethical committee. All procedures were in
accordance with the Helsinki Declaration of 1975 (as revised in
2000).
The patients included in this study exhibited advanced
refractory solid tumours for which no standard therapy existed
and for whom treatment with oxaliplatin was considered
acceptable. Other eligibility criteria were age 418 years, a life
expectancy of at least 12 weeks, and an adequate bone marrow,
liver and renal function. Renal function was characterised by
creatinine clearance estimated by the formula of Cockcroft and
Gault. Patients should not have received oxaliplatin within 3
months before enrolment. Patient characteristics are summarised
in Table 1.
Therapy
Thirty-seven patients were treated with 130mgm
 2 oxaliplatin
every 3 weeks combined with different doses of sorafenib.
Oxaliplatin was administered as 2-h i.v. infusion. Blood samples
were collected during the first treatment cycle. Sorafenib was given
twice a day from the fourth day of the first cycle onwards, that is
sorafenib had not been co-administered when blood samples were
collected for this study.
Assessment of response and toxicity
Response was assessed according to RECIST after the second
treatment cycle, that is 6 weeks after start of treatment (Therasse
et al, 2000). Owing to the relatively early assessment of response, a
15–29% decrease in the sum of the longest diameters of target
lesions was split out of the ‘stable disease’ (SD) category and
defined in deviation from the original RECIST criteria as ‘minor
response’ (MR). ‘Stable disease’ was then defined as neither
sufficient shrinkage to qualify for MR nor sufficient increase to
qualify for ‘progressive disease’ (PD). In the following, patients
exhibiting partial or minor remission were regarded as
‘responders’ and those exhibiting SD or PD were regarded as
‘nonresponders’. The treatment-associated toxicity was assessed
after each treatment cycle according to the Common Toxicity
Criteria (National Cancer Institute, 1999). Oxaliplatin-specific
neuropathy was evaluated by the scale of Le ´vi et al (1992).
Analysis of platinum in plasma and ultrafiltrated plasma
Before, during and after administration of oxaliplatin, 13 blood
samples were collected and cooled and the plasma was separated
by centrifugation (3200g for 5min at 41C) within 30min. For
ultrafiltration, 1ml of plasma was transferred to a Centrisartt
ultrafiltration system (Sartorius AG, Go ¨ttingen, Germany; cutoff
10.000) and centrifuged for 20min at 2000g and 41C. All samples
were immediately frozen and stored at  201C until further
analysis.
Elemental platinum in plasma and ultrafiltrate was determined
by flameless atomic absorption spectrometry using a modification
of a procedure described by Kloft et al (1999a). In brief, an
atomic absorption spectrometer (SpectrAAt Zeeman 220; Varian,
Darmstadt, Germany) equipped with a graphite tube atomisator
and a platinum hollow cathode lamp was used. The temperature
programme was optimised for each matrix and concentration
range. The method was validated and met the international
Table 1 Patient characteristics
Characteristic No. of patients
Total number of patients 37
Sex
Male 26
Female 11
Age (years)
Median 59
Range 32–80
Height (cm)
Median 170
Range 159–190
Mass (kg)
Median 73
Range 55–106
Body surface area (m
2)
Median 1.9
Range 1.5–2.2
Body mass index (kgm
 2)
Median 25
Range 19–34
Creatinine clearance (mlmin
 1)
Median 96
Range 57–239
Number of patients with pretreatment chemotherapy
Containing platinum complexes 28
Containing oxaliplatin 19
Number of pretreatment chemotherapy regimens
Median 3
Range 0–5
Disease site
Colorectal carcinoma 18
Uvea melanoma 5
Gastric cancer 4
Cancer of unknown primary origin 3
Various malignancies 7
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srequirements on bioanalytical methods (Shah et al, 2000; US
Department of Health and Human Services, FDA, CDER and CVM,
2001; Gastl et al, 2003).
Determination of platinum-DNA adducts in WBC
DNA platination in WBC was determined by a four-step procedure
consisting of isolation of WBC out of whole blood, separation of
DNA, quantification of DNA and quantification of platinum bound
to DNA using a modification of the method by Kloft et al (1999b).
In brief, WBC were isolated 0, 4, 24 and 48h after the start of
oxaliplatin infusion within 2h after blood collection using density
gradient centrifugation (30min at 400g and room temperature
using Polymorphprept; Axis-Shield, Oslo, Norway). Two bands
(mononuclear and polymorphonuclear cells) were harvested and
pooled. Then the cells were washed twice with ice-cold PBS to
remove other blood components and the gradient medium. WBC
samples were immediately frozen and stored at  201C until further
analysis.
The isolation of DNA out of WBC was performed by solid-phase
extraction with QIAampt DNA-blood kits (Qiagen, Hilden,
Germany). The isolation procedure consisted of the lysis of WBC
and adsorption of DNA to a silica membrane followed by two
washing steps to remove other cell components. In the last step,
DNA was eluted from the column. All DNA samples were stored at
 201C until further analysis. The DNA concentrations and the
purity of the isolated DNA were determined by UV spectrometry
measuring the absorption at 260, 280 and 320nm. This method was
validated and met the requirements on bioanalytical methods.
The quantification of platinum bound to DNA was performed by
a validated adsorptive stripping voltammetry method. This highly
sensitive method, described by Weber et al (2004), allowed the
determination of platinum with a lower limit of quantification
of 0.4pgml
 1 (Messerschmidt et al, 1992; Gelevert et al, 2001). In
brief, the residue of the dried eluate was decomposed to
mineralisation using a high-pressure asher (HPA, Ku ¨rner,
Rosenheim, Germany). A detailed description of the mineralisation
process is given by Messerschmidt et al (1992). Platinum was then
quantified by adsorptive stripping voltammetry using a Metrohm
Polarecord 626 (Metrohm, Herisau, Switzerland). The concentra-
tion of platinum was evaluated from three standard additions
with sufficient accuracy and precision (relative error o9.8% and
relative standard deviation o8.0%). On the basis of the DNA and
platinum concentrations, the platinum-nucleotide ratio was
calculated using the relative atomic mass of platinum (Ar(plati-
num) ¼195.1) and the relative molecular mass of nucleotides
(Mr(nucleotide) ¼330).
The between-day precision for the whole method consisting of
DNA isolation, DNA and platinum quantification was 11.8%
(relative standard deviation). On the basis of this result, the
method was regarded as being suitable for characterizing
platinum-DNA adduct formation and its interindividual variability
in clinical samples.
Pharmacokinetic data analysis
Individual pharmacokinetic parameters were estimated using a
compartmental approach by means of the validated software
WinNonlint 4.0. (Pharsight Corporation, Mountain View, CA,
USA). The following parameters were estimated by using a
two-compartment model: AUCN, CL, Vss, t1/2l1 and t1/2z.
The peak concentration (Cmax) and the time until the peak
concentration was reached (tmax) were taken directly from the
concentration-time profile.
Besides, the area under the adduct curve (AUA0 48h) and the
AUC0 48h were determined using the linear trapezoidal rule.
Statistical analysis
The statistical analysis was performed using the software SPSS
12.0.1 for Windows. Data distribution was tested by the
Shapiro-Wilk test. For comparisons between groups of patients,
for example, responders vs nonresponders, the Mann–Whitney
test was used. The correlation between pharmacokinetic para-
meters and adduct levels was assessed by the coefficient of
correlation according to Kendall.
RESULTS
Platinum pharmacokinetics in plasma and ultrafiltrate
Figure 1 shows the platinum concentration-time course during the
first 48h after the start of oxaliplatin infusion in plasma as well as
ultrafiltrate during the first treatment cycle. The pharmacokinetic
parameters are summarised in Table 2. In ultrafiltrate, the AUCN
was about 9% compared to the AUCN in plasma.
Time course of platinum-DNA adduct formation in WBC
Figure 2 shows the individual platinum-nucleotide ratios including
the median at the different time points 0h (A0h), 4h (A4h), 24h
(A24h) and 48h (A48h). Before the first oxaliplatin infusion,
platinum adducts were detectable in several patients and this was
attributed to platinum-containing pretreatment. The maximum
platinum-nucleotide ratios (Amax) were observed either 4 or 24h
after the start of infusion in most of the patients. The median Amax
value was 4.43 Pt atoms: 10
6 nucleotides. On the basis of the
platinum-nucleotide ratios, the area under the adduct curve
(AUA0 48h) was calculated. The median AUA0 48h was found to
be 163 Pt atoms h: 10
6 nucleotides.
The interindividual variability of platinum-nucleotide ratios at
all times of observation was considerably higher than that of the
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Figure 1 Mean platinum concentration-time profiles (mean±s.d.;
n¼37) in plasma (K) and ultrafiltrate (J).
Table 2 Platinum pharmacokinetic parameters during the first cycle (Mean±s.d.; n¼37)
Cmax (lgml
 1) AUCN N N (lg.hml
 1) t1/2k1 (h) t1/2z (h) CL (Lh
 1) Vss (L)
Ultrafiltrate 6.69±12.5 9.45±5.11 0.22±0.08 18.7±5.2 14.8±5.02 255±92
Plasma 9.32±13.5 108±25 0.45±0.46 33.7±6.7 1.19±0.40 54.9±18.7
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splasma concentrations. The amount of platinum-DNA adducts was
not affected by sex or other factors such as age, height, weight,
body surface area, body mass index, creatinine clearance and, most
interestingly, platinum pretreatment.
The relationship between pharmacokinetic parameters
(AUC0 48h,C max and CL in plasma/ultrafiltrate) and adduct levels
(A4h, A24h, A48h, AUA0 48h,A max) was examined by means of a
correlation analysis. Figure 3 shows the relationship between area
under the platinum-nucleotide adduct curve (AUA0 48h) and
AUC0 48h in ultrafiltrate (Figure 3A) and plasma (Figure 3B). The
correlation coefficients according to Kendall were 0.041 and
 0.065 for ultrafiltrate and plasma, respectively. Moreover, Amax
was neither correlated to Cmax in ultrafiltrate (r¼ 0.158) nor to
Cmax in plasma (r¼ 0.170).
Response and toxicity
In total, 37 patients were included in this study. Thirty-one
patients received a second treatment cycle and were therefore
evaluable for response. Five out of 31 patients (16.1%) experienced
either partial (one patient) or minor response (four patients). Of
the patients, 45% experienced a stabilisation of previous PD (14
patients) and 39% showed tumour progression (12 patients).
With regard to toxicity, which was assessed after each cycle,
all 37 patients were evaluable for haemato-, nephro- and
hepatotoxicity in the first cycle. In general, the treatment was well
tolerated. Only eight patients (21.6%) experienced toxic effects of
grade 3 during the first cycle and no patient showed toxicity of
grade 4.
Peripheral neurotoxicity, which is typical for oxaliplatin, was
observed in most of the patients (all 37 patients were evaluable).
Grade 1 neurotoxicity was observed in 75.7%, grade 2 in 16.2% and
grade 3 in 8.1% of the patients. No patient experienced grade 4 toxicity.
Relationships between adduct levels and clinical outcome
The relationships between adduct levels and response as well as
the extent of neurotoxic symptoms were analysed. The results are
shown in Tables 3 and 4. Platinum-nucleotide ratios at time points
24 and 48h after the start of infusion were significantly higher
in responders compared to nonresponders (for individual data
points, see Figure 2A). Forty-eight hours after the start of infusion,
responders reached a median platinum-nucleotide ratio that was
threefold higher than in nonresponders (P¼0.007). Besides, Amax
was significantly different between patients with and without
response (P¼0.006). AUA0 48h was higher in responders, but the
difference did not reach statistical significance. Figure 4 shows that
all patients with AUA0 48h values lower than 140 Pt atoms h: 10
6
nucleotides (Figure 4A), as well as patients with Amax values lower
than 4 Pt atoms: 10
6 nucleotides (Figure 5A), were nonresponders.
In patients with grade 2–4 neurotoxicity, median adduct levels
Amax and AUA0 48h were higher compared to patients who
experienced no or mild neurotoxicity (Table 4), which is also
obvious from the respective graphical presentation of individual
data (Figure 2B). However, the difference did not reach statistical
significance in any of the adduct parameters (Figure 4B and 5B).
DISCUSSION
This study was conducted to characterise the kinetics of platinum-
DNA adduct formation in WBC after administration of oxaliplatin
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Figure 3 Relationship between area under the platinum-nucleotide
adduct curve (AUA0 48h) and AUC0 48h in ultrafiltrate (A) and
plasma (B).
Table 3 Comparison of adduct parameters of nonresponders (n¼26) and responders (n ¼5) (Medians with minimum and maximum values)
Nonresponders (n¼26
a,b) Responders (n¼5) P-value
c
A4h (Pt atoms : 10
6 nucl.) 1.48 (0.54–165) 2.23 (1.57–6.34) 0.280
A24h (Pt atoms : 10
6 nucl.)
a 1.62 (0.10–69.4) 5.83 (1.88–18.0) 0.037*
A48h (Pt atoms : 10
6 nucl.)
b 1.14 (0.31–6.69) 3.51 (1.56–7.46) 0.007*
Amax (Pt atoms : 10
6 nucl.) 2.18 (1.00–165) 7.46 (5.83–18.0) 0.006*
AUAc–48h (Pt atoms h:10
6 nucl.)
b 72.0 (18.5–3545) 173 (156–501) 0.071
*Marks a significant result (Po0.05).
aThe A24h sample of one nonresponder was not collected.
bThe A48h samples of three nonresponders were not collected.
cMann–Whitney
U-test.
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Figure 2 Individual and median platinum-nucleotide ratios (n¼37); (A)
of nonresponders (K) and responders (J); (B) of patients with low
(0–1; K) and high (2–4; J) grade of neurotoxicity.
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sand to explore the relation between adduct formation and clinical
effects. Although there are numerous clinical studies on the
platinum-DNA adduct formation after cisplatin and carboplatin
there are only preliminary data available on oxaliplatin in a few
patients (Allain et al, 1996; Liu et al, 2002).
As oxaliplatin forms considerably less adducts after therapeutic
doses than the other two platinum complexes, an assay with higher
sensitivity was required. Therefore, we chose adsorptive voltam-
metry, which allows the quantification of platinum concentrations
down to 0.4pgml
 1, that is, 0.05 platinum atoms: 10
6 nucleotides
can be measured in a sample of 70mg DNA (Weber et al, 2004).
DNA quantification as well as platinum measurements in DNA
samples were validated and showed sufficient accuracy and
precision.
In the two published investigations dealing with the platinum-
DNA adduct formation after administration of oxaliplatin, the
ICP-MS technique was used for the determination of DNA-bound
platinum (Allain et al, 1996; Liu et al, 2002). The platinum-
nucleotide ratios measured in our study were in the same range of
the data presented by Allain et al (1996) who examined six patients
in two cycles. In the study of Liu et al (2002), however, the
platinum-nucleotide values were 1000 times higher than in our
investigation and the study of Allain et al (1996), although only
60mgm
 2 oxaliplatin were administered. According to the
authors, the considerably higher adduct values were caused by
the fact that not only DNA adducts but also protein adducts were
measured. Therefore, the data of Liu et al (2002) are probably
artefacts and cannot be compared with our study.
Various parameters can be derived from platinum-DNA adduct
levels. Besides the maximum adduct level (Amax), the area under
the adduct curve (AUA) was calculated to characterise the DNA
platination over the whole period of observation. This parameter
was used by Schellens et al (1996) and Veal et al (2001) after
cisplatin administration. Other authors used the adduct values
measured at a certain time (Dabholkar et al, 1992; Gupta-Burt et al,
1993; Boffetta et al, 1998), the maximum of all values measured in
several cycles (Reed et al, 1988) or the measurability of adducts
(Reed et al, 1986; Poirier et al, 1987). The interindividual
variability of adduct levels after administration of oxaliplatin was
large, especially in comparison to the pharmacokinetic parameters.
Large interindividual differences were also observed after admin-
istration of cisplatin and carboplatin (Reed et al, 1993). As
sorafenib was co-administered only from day 4 of the first cycle
onwards, the effect of sorafenib on adduct formation can be
excluded in our study.
So far, patient-individual factors influencing the extent of DNA
platination were investigated only in a small number of patients for
cisplatin and carboplatin. One possible parameter that could
influence adduct formation is platinum exposure in ultrafiltrate.
The results of previous studies investigating a possible correlation
between pharmacokinetic parameters in ultrafiltrate and adduct
parameters were not consistent. Peng et al (1997) and Veal et al
(2001) did not observe any correlation between platinum
pharmacokinetics and adduct formation except for cisplatin at
Table 4 Comparison of adduct parameters of patients with low (n¼28) or high grade neurotoxicity (n¼9) (Medians with minimum and maximum
values)
Grade 0–1 (n¼28
a,b) Grade 2–4 (n¼9) P-value
c
A4h (Pt atoms : 10
6 nucl.) 1.81 (0.54–165) 2.23 (1.02–23.7) 0.876
A24h (Pt atoms : 10
6 nucl.)
a 2.14 (0.10–69.4) 4.91 (0.10–7.47) 0.428
A48h (Pt atoms : 10
6 nucl.)
b 1.25 (0.31–5.60) 2.11 (0.31–7.46) 0.370
Amax (Pt atoms : 10
6 nucl.) 2.27 (1.00–165) 5.83 (1.03–23.7) 0.319
AUA0-48h (Pt atoms h: 10
6 nucl.)
b 86.0 (26.2–3545) 173 (18.5–387) 0.592
aThe A24h-sample of one patient with low grade neurotoxicity was not collected.
bThe A48h-samples of four patients with low grade neurotoxicity were not collected.
cMann–Whitney U-test.
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Figure 5 Individual and median maximum platinum-nucleotide ratio
(Amax); (A) of nonresponders (n¼26) and responders (n¼5); (B)o f
patients with low (0–1; n¼9) and high (2–4; n¼28) grade of
neurotoxicity.
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sone particular time point. In contrast, Schellens et al (1996) found a
strong correlation between AUCUF and AUA (r¼0.78; Po0.0001).
Recently, a correlation between carboplatin AUC and platinum-
DNA adduct levels was reported after high-dose carboplatin in
children (Veal et al, 2007). These contradictory results indicate the
importance of intracellular processes, for example, cellular uptake,
inactivation by glutathione and DNA repair. Another factor that
may have influenced the adduct levels is platinum pretreatment,
particularly as some patients in our study exhibited measurable
adduct levels before oxaliplatin administration. However, pretreated
patients did not show higher adduct parameters (measured adduct
levels at any time, Amax and AUA) than those patients who were not
pretreated with platinum complexes. In addition, demographic
factors were examined concerning their influence on adduct
formation, for example, sex and age. However, no correlation was
found for any of these patient characteristics (Fichtinger-Schepman
et al, 1990; Veal et al,2 0 0 1 ) .
There are various reports on the possible relationships between
DNA platination and tumour response after cisplatin- and
carboplatin-based chemotherapy. In most of the studies, a large
variability of adduct levels was observed, leading to overlapping
ranges of adduct values for responders and nonresponders.
Nevertheless, in some studies, significant differences concerning
the extent of DNA platination between both groups were shown
(Reed et al, 1987, 1988, 1993; Parker et al, 1991; Schellens et al,
1996). In contrast, other authors did not find a positive correlation
between adduct formation and response (Gupta-Burt et al, 1993;
Motzer et al, 1994; Boffetta et al, 1998). In our study, the adduct
levels 24 and 48h as well as Amax were correlated to response. A4h
and AUA0 48h were considerably higher in responders than in
patients with stable or progressive disease, but statistical
significance was not reached. It is remarkable that all patients
with AUA0 48h values lower than 140 Pt atoms h: 10
6 nucleotides
were nonresponders. Provided that a dose-dependence of oxali-
platin-DNA adduct formation can be shown, an AUA in this range
may serve as a target value for individual dose escalation to
increase the probability of a tumour response. However, this has to
be confirmed in a larger group of patients. Moreover, adduct levels
should be investigated in a more homogeneous patient population,
especially with regard to the tumour entity and stage.
With regard to a possible correlation to toxicity, we focused on
the neurotoxicity of oxaliplatin, which is often dose-limiting. In
our study, only the acute peripheral neurotoxicity was observed
because a cumulative dose of 700mgm
 2, after which the chronic
sensory neurotoxicity normally occurs, was not reached. Although
patients with weak or no neurotoxic symptoms exhibited smaller
adduct values than patients with a peripheral neurotoxicity grade
2–4, the difference was not significant. One may speculate that in a
larger group of patients, significance would have been found.
Nevertheless, the association between adduct levels and neuro-
toxicity seems to be weaker compared with the relationship
between adduct levels and tumour response. The results of studies
investigating the correlation between DNA platination and toxicity
after cisplatin- or carboplatin-based treatment were inconsistent.
In two studies no correlation was found (Bonetti et al, 1996;
Ghazal-Aswad et al, 1999), whereas others reported an association
between DNA platination and haematotoxicity. High platinum-
adduct levels were associated with a high degree of thrombo-
cytopaenia (Schellens et al, 1996) and leukopaenia (Veal et al,
2001). However, the administration schemes, the tumour entities
of the patients and the analytical methods used were different,
which may explain these conflicting results.
In conclusion, relationships between oxaliplatin-DNA adduct
formation and clinical efficacy/toxicity were analysed for the first
time. The observed correlation between adduct levels and response
indicates the potential of these measurements to serve as
pharmacodynamic end point in clinical trials. It seems to be
worthwhile to study platinum-DNA adduct formation in a larger
group of patients to define target adduct values that may be used
for individual dose escalation.
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